Pfizer C4531029 - Asthma

  • Study Sponsor and Protocol Number: 
    Pfizer / C4531029
  • Specialty:
    Pulmonology
  • Type:
    Investigational Drug
  • Inclusion:
    Age >40 to <85
    BMI >16 kg/m2
    Moderate-to-severe asthma per GINA (> 12 months), with minimum daily treatment of medium to high dose ICS-LABA. Triple therapy LAMA is allowable (any dose)
    ≥1 exacerbation in past 12 months (steroid or hospitalization)
    •